Sector News

Categories

Borderless Insights

Image
Negotiating Terms with a New Employer
Image
Beyond Flowers and Platitudes: Reclaiming the Essence of International Women’s Day
Image
Visionary or ‘Stuck-in-the-Mud’? Where are you on Workplace Flexibility?

Roche to pay up to $489 mln for next-generation antibody developer

December 22, 2014
Life sciences
(Reuters) – Roche has agreed to pay up to $489 million to acquire Austrian biotech company Dutalys, a specialist in the discovery and development of so-called bi-specific antibodies, the Swiss drugmaker said on Thursday.
 
Bi-specific antibody therapy is a fast-emerging technology that could prove more potent than conventional antibodies, which have become mainstay treatments for an array of cancers.
 
Roche will make an upfront cash payment of $133.75 million to shareholders in the Vienna-based company and make additional payments of up to $355 million if certain predetermined milestones are reached.
 
Dutalys has developed a proprietary technology, known as DutaMab, but its programmes are still at an early stage in the drug development process. Roche said the bi-specific antibodies produced with this platform could provide novel molecules for several therapeutic areas, though it gave no details.
 
The deal strengthens Roche’s leading position in the development of therapeutic antibodies, an area in which it already boasts several multibillion-dollar-a-year sellers, including Avastin and Herceptin for cancer.
 
Bi-specific antibodies are artificial proteins composed of fragments of two different monoclonal antibodies, which can bind in two different places in a disease pathway. Roche believes that the DutaMab technology, which creates fully human bi-specific antibodies, promises particularly good binding and stability.
 
Privately owned Dutalys was founded in April 2010. It is supported by seed financing from Austria Wirtschaftsservice, research grants from the Austrian Research Promotion Agency and the Technology Agency of the City of Vienna as well as funding from the Austrian Academic Business Incubator.
 
(Reporting by Ben Hirschler; Editing by David Goodman)

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

Read more
April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

Read more
April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

Read more
More news

How can we help you?

We're easy to reach